In the realm of acute myeloid leukemia (AML) treatment, the paradigm is shifting towards combination therapies as a promising avenue to enhance therapeutic efficacy and combat treatment resistance. As the scientific community delves deeper into exploring the intricate mechanisms underlying AML pathogenesis and progression, the integration of diverse treatment modalities emerges as a beacon of hope in revolutionizing patient outcomes.

Recent advances have showcased the potential of combining different classes of therapeutic agents, such as targeted therapies, immunotherapies, and conventional chemotherapeutics, to synergistically target malignant cells while mitigating the risk of relapse and resistance. These innovative approaches not only demonstrate enhanced anti-leukemic activity but also pave the way for personalized treatment strategies tailored to individual patient profiles.

Despite these significant strides, challenges loom large on the horizon of AML combination therapy research. The need to unravel the complex interplay between tumor cells, the immune microenvironment, and therapeutic agents remains a critical priority. Additionally, optimizing dosing schedules, minimizing off-target effects, and deciphering mechanisms of treatment resistance pose formidable obstacles that demand meticulous investigation and innovative solutions.

Considering the evolving landscape of AML treatment, we invite researchers from across the scientific community to contribute their expertise and insights to our upcoming article collection on Combination Therapies in AML. By sharing your research findings, novel methodologies, and clinical perspectives, we aim to foster collaboration, catalyze discoveries, and shape the future of AML therapy towards improved patient outcomes.

As we look to the future, this Research Topic aims to provide a comprehensive overview of combination therapies research, while shedding light on the exciting possibilities that lie ahead. By sharing your insights, original research, reviews and case studies, you can contribute to shaping the trajectory of AML care.

Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.

Submit your idea

Impact

Frontiers in Oncology

Submit your idea

Impact